CRVO news

CervoMed announced peer-reviewed studies supporting neflamapimod as a DLB treatment. Positive trial biomarkers reinforce the drug's mechanism and rationalize further clinical development.

CervoMed has introduced a stable 50 mg tablet formulation to replace a previous capsule, paving the way for a higher, twice-daily dosing regimen. This regulatory and manufacturing progress aims to reduce clinical trial execution risk for the age-related brain disorder treatment.

CervoMed announced initial 12-week biomarker results from its Phase 2a trial of neflamapimod for nfvPPA will be presented as a late-breaking oral session at the ISFTD conference in October.

CervoMed received Innovation Passport Designation for neflamapimod in dementia with Lewy bodies; additionally, Q2 financial results and updates for both DLB and nonfluent variant primary progressive aphasia programs were provided. The data supports a pivotal Phase 3 strategy.

CervoMed Inc. received an Innovation Passport for neflamapimod under the UK's ILAP program to accelerate its development for Lewy body dementia. Regulatory approval marks a significant step toward addressing this unmet medical need.

CervoMed released new analyses from its Phase 2b trial reinforcing neflamapimod's efficacy. The data supports selecting the 50 mg dose for Phase 3, enhancing investor confidence in the company's dementia pipeline.

CervoMed Inc. completed a registered direct offering of 2.5 million shares at $4.00 per share, raising $10 million gross proceeds for working capital and general corporate purposes. The funding supports the clinical-stage biotech's development of neflamapimod for age-related brain disorders, with Ph…